×

Molecular diagnostic test for cancer

  • US 10,214,777 B2
  • Filed: 08/13/2015
  • Issued: 02/26/2019
  • Est. Priority Date: 09/15/2010
  • Status: Active Grant
First Claim
Patent Images

1. A method of diagnosing and treating an individual as having a DNA damage response deficient (DDRD) cancer comprising;

  • a. measuring expression levels of at least two genes in a test sample of tumour cells obtained from the individual to determine a test score, wherein the at least two genes are selected from the group consisting of CXCL10, IDO1, CD2, GBP5, ITGAL, LRP4, APOL3, CDR1, FYB, TSPAN7, RAC2, KLHDC7B, GRB14, AC138128.1, KIF26A, CD274, CD109, ETV7, MFAP5, OLFM4, PI15, FOSB, FAM19A5, NLRC5, PRICKLE1, EGR1, CLDN10, ADAMTS4, SP140L, ANXA1, RSAD2, ESR1, IKZF3, OR2I1P, EGFR, NAT1, LATS2, CYP2B6, PTPRC, PPP1R1A, and AL137218.1; and

    b. treating the individual with a DNA-damage therapeutic agent, wherein the individual is diagnosed as having the DDRD cancer because a test score of the test sample exceeds a threshold score, and said exceeding occurs if the test score, based on the expression levels of the at least two genes, exceeds a threshold score based on the same genes.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×